Legal & General Group PLC Alaunos Therapeutics, Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 22, 2022	SELL	$0.41 - $1.24 $68,884 - $208,333	-168,011 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.89 $95,216 - $165,100	87,355 Added 108.31%	168,011 $183,000
Q3 2021 Nov 15, 2021	BUY	$1.44 - $2.73 $60,985 - $115,618	42,351 Added 110.56%	80,656 $146,000
Q2 2021 Aug 12, 2021	SELL	$2.63 - $3.67 $4,910 - $6,851	-1,867 Reduced 4.65%	38,305 $102,000
Q1 2021 May 17, 2021	BUY	$2.82 - $5.6 $17,957 - $35,660	6,368 Added 18.84%	40,172 $145,000
Q4 2020 Feb 12, 2021	SELL	$2.09 - $3.09 $19,641 - $29,039	-9,398 Reduced 21.75%	33,804 $85,000
Q3 2020 Nov 13, 2020	SELL	$2.39 - $3.43 $22,769 - $32,677	-9,527 Reduced 18.07%	43,202 $109,000
Q2 2020 Aug 14, 2020	BUY	$2.2 - $3.71 $5,860 - $9,883	2,664 Added 5.32%	52,729 $173,000
Q1 2020 May 14, 2020	BUY	$1.9 - $4.98 $12,572 - $32,952	6,617 Added 15.23%	50,065 $122,000
Q4 2019 Feb 13, 2020	BUY	$3.95 - $5.35 $25,706 - $34,817	6,508 Added 17.62%	43,448 $205,000
Q3 2019 Nov 13, 2019	BUY	$4.13 - $6.94 $25,337 - $42,576	6,135 Added 19.92%	36,940 $158,000
Q2 2019 Aug 14, 2019	BUY	$3.98 - $6.2 $19,661 - $30,628	4,940 Added 19.1%	30,805 $179,000
Q4 2018 Feb 15, 2019	BUY	$1.61 - $3.62 $9,746 - $21,915	6,054 Added 30.56%	25,865 $48,000
Q3 2018 Nov 20, 2018	SELL	$2.26 - $3.27 $29,965 - $43,356	-13,259 Reduced 40.09%	19,811 $63,000
Q2 2018 Aug 10, 2018	SELL	$3.02 - $4.94 $10,379 - $16,978	-3,437 Reduced 9.41%	33,070 $100,000
Q1 2018 May 17, 2018	SELL	$3.46 - $5.14 $36,177 - $53,743	-10,456 Reduced 22.26%	36,507 $143,000
Q4 2017 Feb 13, 2018	BUY	$4.0 - $6.54 $187,852 - $307,138	46,963	46,963 $193,000

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $517M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account